Literature DB >> 2410428

Acute-phase-proteins and parameters of humoral immunity in patients with advanced Hodgkin's disease.

C C Zielinski, P Preis, P Aiginger, M M Eibl.   

Abstract

Serum concentrations of acute-phase-proteins C-reactive protein (CRP), alpha 1-antitrypsin (AAT), alpha 1-acid glycoprotein (AGP) as well as levels of immunoglobulins G, A and M and of complement components C3 and C4 were evaluated in 15 patients with advanced (stages III and IV) Hodgkin's disease. Of these patients 9 suffered from B symptoms including pruritus, night sweats and fever. While all patients had highly increased concentrations of CRP and AAT and 11 patients also had elevated levels of AGP in their sera, these concentrations were significantly (P less than 0.001) reducible by the administration of chemotherapy. Patients with B symptoms also had significantly higher concentrations of CRP (P less than 0.02), AAT (P less than 0.05) and AGP (P less than 0.05) in their sera than patients without. Plasmapheresis which was performed in 3 patients did not achieve a long-lasting reduction of serum concentrations of any acute-phase-protein tested. Complement components C3 and C4 exhibited a similar behaviour as acute-phase-proteins in that they were elevated in patients with B symptoms and reducible by the administration of chemotherapy (P less than 0.001 and P less than 0.02, respectively). We conclude that serum concentrations of CRP, AAT and AGP can serve as useful markers for the assessment of tumour activity in patients with advanced Hodgkin's disease. Whereas the concentrations of immunoglobulins G and A in patients were comparable to normal controls, IgM was significantly (P less than 0.05) reduced in patients who had received chemotherapy, but not in those who were newly diagnosed and had not received any treatment. Thus, chemotherapy lowered serum concentrations of IgM without influencing levels of IgG and IgA.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410428     DOI: 10.1007/bf00402504

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  21 in total

1.  Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).

Authors:  A Santoro; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors:  V T Devita; A A Serpick; P P Carbone
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391

3.  Plasmapheresis in patients with disseminated cancer: clinical results and correlation with changes in serum protein. The concept of "nonspecific blocking factors".

Authors:  L Israel; R Edelstein; P Mannoni; E Radot; E M Greenspan
Journal:  Cancer       Date:  1977-12       Impact factor: 6.860

4.  Absence of prostaglandin stimulated increase in acute phase proteins in systemic sclerosis.

Authors:  J T Whicher; M F Martin; P A Dieppe
Journal:  Lancet       Date:  1980-11-29       Impact factor: 79.321

5.  Impaired humoral immunity in treated Hodgkin's disease.

Authors:  S A Weitzman; A C Aisenberg; G R Siber; D H Smith
Journal:  N Engl J Med       Date:  1977-08-04       Impact factor: 91.245

6.  Serum C-reactive protein levels in disease.

Authors:  J J Morley; I Kushner
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

7.  Prostaglandin-producing suppressor cells in Hodgkin's disease.

Authors:  J S Goodwin; R P Messner; A D Bankhurst; G T Peake; J H Saiki; R C Williams
Journal:  N Engl J Med       Date:  1977-11-03       Impact factor: 91.245

8.  In vivo and in vitro studies on nonspecific blocking factors of host origin in cancer patients. Role of plasma exchange as an immunotherapeutic modality.

Authors:  L Israël; R Edelstein
Journal:  Isr J Med Sci       Date:  1978-01

9.  Control of the acute phase response. Demonstration of C-reactive protein synthesis and secretion by hepatocytes during acute inflammation in the rabbit.

Authors:  I Kushner; G Feldmann
Journal:  J Exp Med       Date:  1978-08-01       Impact factor: 14.307

10.  The liver as the site of C-reactive protein formation.

Authors:  J Hurlimann; G J Thorbecke; G M Hochwald
Journal:  J Exp Med       Date:  1966-02-01       Impact factor: 14.307

View more
  2 in total

1.  Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?

Authors:  Pierre Y Salaun; Thomas Gastinne; Caroline Bodet-Milin; Loïc Campion; Pierre Cambefort; Anne Moreau; Steven Le Gouill; Christian Berthou; Philippe Moreau; Françoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-05       Impact factor: 9.236

2.  Evaluation correlates C-reactive protein with advanced stage Hodgkin's lymphoma and response to treatment in a tertiary university hospital in Brazil.

Authors:  Talita Máira Bueno da Silveira da Rocha; Ana Luiza Pereira Miranda Silva; Sérgio Costa Fortier; Carlos Sérgio Chiattone
Journal:  Rev Bras Hematol Hemoter       Date:  2015-06-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.